235 related articles for article (PubMed ID: 9139216)
41. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity.
Motzer RJ; Mazumdar M; Bosl GJ; Bajorin DF; Amsterdam A; Vlamis V
J Clin Oncol; 1996 Apr; 14(4):1098-105. PubMed ID: 8648363
[TBL] [Abstract][Full Text] [Related]
42. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer.
Reckzeh B; Merte H; Pflüger KH; Pfab R; Wolf M; Havemann K
J Clin Oncol; 1996 Apr; 14(4):1071-6. PubMed ID: 8648359
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery.
Wada H; Hitomi S; Teramatsu T
J Clin Oncol; 1996 Apr; 14(4):1048-54. PubMed ID: 8648356
[TBL] [Abstract][Full Text] [Related]
44. [Prevalence of Helicobacter pylori infection in stomach carcinoma].
Hatz RA; Lehn N; Leyh S; Kaps MF; Bayerdörffer E; Stolte M; Schildberg FW
Chirurg; 1996 Apr; 67(4):403-8. PubMed ID: 8646928
[TBL] [Abstract][Full Text] [Related]
45. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
[TBL] [Abstract][Full Text] [Related]
46. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
[TBL] [Abstract][Full Text] [Related]
47. Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type.
Schlegelberger B; Zwingers T; Hohenadel K; Henne-Bruns D; Schmitz N; Haferlach T; Tirier C; Bartels H; Sonnen R; Kuse R
J Clin Oncol; 1996 Feb; 14(2):593-9. PubMed ID: 8636776
[TBL] [Abstract][Full Text] [Related]
48. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.
Pettengell R; Radford JA; Morgenstern GR; Scarffe JH; Harris M; Woll PJ; Deakin DP; Ryder D; Wilkinson PM; Crowther D
J Clin Oncol; 1996 Feb; 14(2):586-92. PubMed ID: 8636775
[TBL] [Abstract][Full Text] [Related]
49. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
[TBL] [Abstract][Full Text] [Related]
50. The value of high-dose methotrexate-based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone.
Ham SJ; Hoekstra HJ; van der Graaf WT; Kamps WA; Molenaar WM; Schraffordt Koops H
J Clin Oncol; 1996 Feb; 14(2):490-6. PubMed ID: 8636762
[TBL] [Abstract][Full Text] [Related]
51. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
[TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: implications for management.
Heslin MJ; Woodruff J; Brennan MF
J Clin Oncol; 1996 Feb; 14(2):473-8. PubMed ID: 8636760
[TBL] [Abstract][Full Text] [Related]
53. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.
Puc HS; Heelan R; Mazumdar M; Herr H; Scheinfeld J; Vlamis V; Bajorin DF; Bosl GJ; Mencel P; Motzer RJ
J Clin Oncol; 1996 Feb; 14(2):454-60. PubMed ID: 8636757
[TBL] [Abstract][Full Text] [Related]
54. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial.
Pont J; Albrecht W; Postner G; Sellner F; Angel K; Höltl W
J Clin Oncol; 1996 Feb; 14(2):441-8. PubMed ID: 8636755
[TBL] [Abstract][Full Text] [Related]
55. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.
Conte PF; Bruzzone M; Carnino F; Gadducci A; Algeri R; Bellini A; Boccardo F; Brunetti I; Catsafados E; Chiara S; Foglia G; Gallo L; Iskra L; Mammoliti S; Parodi G; Ragni N; Rosso R; Rugiati S; Rubagotti A
J Clin Oncol; 1996 Feb; 14(2):351-6. PubMed ID: 8636743
[TBL] [Abstract][Full Text] [Related]
56. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP
Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143
[TBL] [Abstract][Full Text] [Related]
57. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R; Cobcroft R; Herrmann R; Van Der Weyden M; Lowenthal RM; Page F; Garson OM; Juneja S
Blood; 1996 Mar; 87(5):1710-7. PubMed ID: 8634416
[TBL] [Abstract][Full Text] [Related]
58. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis.
Marino P; Preatoni A; Cantoni A
Cancer; 1995 Aug; 76(4):593-601. PubMed ID: 8625152
[TBL] [Abstract][Full Text] [Related]
59. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).
Diehl V; Loeffler M; Pfreundschuh M; Ruehl U; Hasenclever D; Nisters-Backes H; Sieber M; Smith K; Tesch H; Geilen W
Ann Oncol; 1995 Nov; 6(9):901-10. PubMed ID: 8624293
[TBL] [Abstract][Full Text] [Related]
60. Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
Dreyfuss AI; Clark JR; Norris CM; Rossi RM; Lucarini JW; Busse PM; Poulin MD; Thornhill L; Costello R; Posner MR
J Clin Oncol; 1996 May; 14(5):1672-8. PubMed ID: 8622087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
